# Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis

> **NCT04006080** · PHASE4 · UNKNOWN · sponsor: **Guy's and St Thomas' NHS Foundation Trust** · enrollment: 30 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** Vedolizumab

## Key facts

- **NCT ID:** NCT04006080
- **Lead sponsor:** Guy's and St Thomas' NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006080, "Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04006080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*